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Background: We tested the hypothesis that vardenaﬁl, a common drug used for improving erectile dysfunction and able to partially normalize
transepithelial chloride transport in cystic ﬁbrosis (CF), modulates CF lung inﬂammation.
Methods: Inﬂammatory markers in lungs of F508del-CF and wild-type mice were monitored in response to lipopolysaccharide from Pseudomonas
aeruginosa (LPS). The effect of pretreatment with vardenaﬁl (0.14 mg/kg) was evaluated.
Results: A latent inﬂammatory status, characterized by neutrophil inﬁltrate, mouse macrophage inﬂammatory protein (MIP)-2 and tumor necrosis
factor (TNF)-α, was found in baseline conditions in F508del-CF mice. Inﬂammatory markers were increased after LPS with higher responses in
CF. Vardenaﬁl globally attenuated inﬂammatory responses in both genotypes however reduction of macrophage inﬁltration, macrophage chemoat-
tractant chemokine and interleukin-1β was observed in the CF group only.
Conclusion: Vardenaﬁl reduces lung inﬂammation with a more pronounced effect in F508del-CF mice, particularly on macrophage cell markers.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; CFTR; Phosphodiesterase type 5 inhibitor; CF pharmacotherapy; Immunomodulation; Inﬂammation1. Introduction
Inflammation plays a critical role in lung disease develop-
ment and progression in cystic fibrosis (CF) [1]. Increased
levels of neutrophils and pro-inflammatory cytokines have
been characteristically found in bronchoalveolar lavage (BAL)
from CF patients [2,3] and from CF mouse models of lung
infection with Pseudomonas aeruginosa or with components
of the bacterial wall, such as lipopolysaccharide (LPS) [4–6].
Vardenafil is a highly selective inhibitor of cyclic guanosine
monophosphate (cGMP)-dependent phosphodiesterase type 5⁎ Corresponding author at: Louvain Centre for Toxicology and Applied Phar-
macology (LTAP), Avenue Hippocrate 10, Franklin Tower-entry F, BP-6724,
B1200 – Brussels – Belgium. Tel.: +32 2 764 67 24; fax: +32 2 764 69 32.
E-mail address: teresinha.leal@uclouvain.be (T. Leal).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2012.03.003(PDE5) commonly used for improving erectile dysfunction
[7]. We have previously shown that intraperitoneal injection
[8] or topical nasal application [9] of PDE5 inhibitors, sildenafil
or vardenafil, to CF mice homozygous for the most common
CFTR (CF transmembrane conductance regulator) mutation,
the F508del (c.1521_1523delCTT) mutation, corrects reduced
chloride transport across the respiratory epithelium. As com-
pared to sildenafil, vardenafil is more potent [7] and its CFTR
correcting effect is more prolonged [8]. The mechanism con-
necting abnormal transepithelial chloride transport to triggering
and perpetuation of inflammatory responses in CF has not been
fully elucidated. However it could be expected that correcting
the abnormal CFTR ion channel function would attenuate
chronic airway inflammation. Therefore, we hypothesized that
pre-treatment with vardenafil at a dose regimen that corrects
transepithelial chloride transport [8,9], as shown with otherby Elsevier B.V. All rights reserved.
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inflammation in CF [6]. We examined the effect of pre-
treatment with a single systemic therapeutic dose of vardenafil
on cellular and molecular components of the inflammatory
response induced by LPS from P. aeruginosa in the lungs
of F508del-CF mice.2. Methods
2.1. Animal model
Young adult CF mice homozygous for the F508del-CFTR
mutation in the 129/FVB outbred background (cftr tm1Eur) [11]
and their normal homozygous wild-type littermates were stud-
ied. Mouse age ranged from 8 to 16 weeks and their weights be-
tween 20 and 30 g. The animals were housed at the Animal Care
Facility of our University following recommendations of the
Federation of European Laboratory Animal Science Associations
[12]. To prevent CF intestinal obstruction, Movicol (55.4 g/L;
Norgine, Heverlee, Belgium)was administered in acidified drink-
ing water. Mice were genotyped at 21 days of age by using
Taqman quantitative PCR, as previously described [6]. These
studies and procedures were approved by the local Ethics
Committee for Animal Welfare and conformed to the European
Community regulations for animal use in research (CEE n° 86/
609).2.2. Vardenafil treatment
Stock solutions of 0.07 mg/ml vardenafil HCl (Bayer, West
Haven, Germany) were prepared in saline, stored at 4 °C, and
used within 4 days after preparation. Treatment with vardenafil
was performed in non-anesthetized animals, as a single i.p.
administration at a dose of 0.14 mg/kg body weight and a vol-
ume of 50 μl/animal. The same volume of sterile saline was
used as placebo.2.3. Induction of lung inflammation
One hour after vardenafil or saline treatment, sex and
weight-matched F508del-CF and normal homozygous wild-
type mice were anesthetized with an i.p. mixture of 100 mg/
kg ketamine (Parke-Davis, Ann Arbor, MI, USA) and 15 mg/
kg xylazine (Bayer, Leverkusen, Germany). Acute lung inflam-
mation was induced by LPS from P. aeruginosa (Sigma Chem-
ical, St. Louis, MO, USA) prepared in saline and administered
intratracheally using a laryngoscope and a fine pipette tip.
In order to track at a single time point after LPS challenge,
both the early humoral and the late cell infiltrating components
of the inflammatory response, a volume of 50 μl LPS solution
was administered at two consecutive doses (50 μg and
100 μg/25 g body weight) with a 21 h interval between doses.
This challenge method enables to track both cytokine and cellu-
lar responses to induction of inflammation.2.4. Bronchoalveolar lavage (BAL)
Three hour after the last LPS tracheal instillation, the mice
were killed by i.p. injection of 20 mg sodium pentobarbital
(Abbott, Chicago, IL, USA). BAL was performed by cannu-
lating the trachea and lavaging with 1.5 ml sterile saline as pre-
viously described [6]. The BAL fluid was centrifuged (250×g,
10 min, 4 °C) and the supernatant was aliquoted and stored
at −80 °C for further biochemical measurements. Differential
cell counts were performed on cytospin preparations using
DiffQuick staining (Dade, Brussels, Belgium).
2.5. Biochemical analysis
Lactate dehydrogenase (LDH) activity in BAL was evaluat-
ed spectrophotometrically based on the catalytic oxidation of
L-lactate to pyruvate with concomitant reduction of NAD (nico-
tinamide adenine dinucleotide). The enzyme activity was mea-
sured by monitoring NADH formation at 340 nm. Linearity of
the test ranges from 20 to 3800 U/L.
2.6. Cytokine and chemokine assays
The pro-inflammatory cytokines: tumor necrosis factor
(TNF)-α, interleukin (IL)-1β and IL-6; and the chemokines:
keratinocyte chemoattractant (KC), mouse macrophage inflam-
matory protein (MIP)-2 and chemokine C-C motif ligand
(CCL)-2, were monitored in BAL fluid following the corre-
sponding manufacturers’ protocols using a standard sandwich
enzyme-linked immunosorbent assay (ELISA). TNF-α was
purchased from BD Pharmigen (San Diego, CA), all other
cyto/chemokines were from R&D Systems (Minneapolis,
MN, USA). The lower limit of detection of all cyto/chemokines
was 15.6 pg/ml and that of CCL-2 was 3.8 pg/ml.
Biochemical and cyto/chemokine analyses were performed
in duplicate by personnel blinded with respect to the treatment
groups.
2.7. Lung histopathology
Lavaged lungs were flushed with 0.9% NaCl and then
completely immersed in 4% buffered paraformaldehyde. Spec-
imens were embedded in paraffin blocks. Sections (5 μm thick-
ness) were then prepared for light microscopy. Slides were
stained with hematoxilin and eosin.
2.8. Statistics
Statistical analysis was performed using JMP8 software
(SAS Institute, Cary, NC, USA). Prior to statistical analysis,
data distributions were checked for normality (Shapiro-Wilk
test). Data are expressed as means (± SEM). Between-group
comparisons were evaluated using one-way analysis of vari-
ance (ANOVA). Posthoc comparisons were performed using
Student's t test or Tukey-Kramer honestly significant differ-
ence (HSD) test, for two or more than 2x levels, as adequate.
The alpha level was adjusted following Bonferroni correction
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Fig. 1. Tissue integrity marker (lactate deshydrogenase (LDH) activity,
expressed as U/L; panel A) and cell composition of the bronchoalveolar lavage
(BAL) under baseline conditions and after intratracheal instillation of LPS from
Pseudomonas aeruginosa in wild-type (WT; white bars) and F508del-CF (black
bars) mice with and without pre-treatment of vardenafil (0.14 mg/kg body
weight), given as a single intraperitoneal administration. Total cells counts
(panel B); neutrophil cell counts (panel C). Values are means±SEM obtained
from 4–8 animals per group from 2 representative experiments. p values denote
levels of significance measured in vardenafil-treated group compared with the
corresponding non-treated group or to the wild-type group.
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means of normally distributed variables are not different, and
that variances of populations are homogeneous (Snedecor's F
test). Null hypothesis was rejected at pb0.05.
3. Results
NaCl instillation did not influence any monitored inflamma-
tory marker. Indeed, when comparing expression of cytokines
or chemokines as well as total cell count and cell composition
profile obtained in saline-treated with those corresponding values
obtained in naive untreated conditions (data not shown), no
significant difference could be detected neither in F508del-CF
nor in wild-type mice. Therefore, in this work values obtained
under NaCl treatment were considered as control reference
values.
Under control conditions, F508del-CF and wild-type mice
showed slight differences in their lung inflammatory pheno-
type. An almost twice as high increase in LDH activity, an
indicator of tissue injury, was observed in CF compared to
wild-type mice (Fig. 1A). The mean (SEM) total cell count in
BAL was 22.9 (3.1) x 103 in the wild-type group and 24.4
(6.1) x 103 in the CF group, and did not differ between the
two groups (Fig. 1B). However, as illustrated in Fig. 1 C, neu-
trophil counts were significantly higher in CF BAL (11.0 (0.4)
x 103) compared to wild-type BAL (0.7 (0.1) x 103; p=0.02).
These data confirmed the presence of a consistent neutrophilia
in CF mice in control, non challenged conditions. Accordingly,
the relative contribution of cell populations in BAL differed
according to the genotype. Indeed, in wild-type BAL, macro-
phages corresponded to the vast majority (97%) of the cell pop-
ulation while in CF BAL a distinct pattern was observed with
neutrophils corresponding to around 45% of total cells. As for
the basal expression of chemokines and pro-inflammatory cyto-
kines (Fig. 2A-F), MIP-2 and TNF-α levels (Fig. 2A, D) were
found to be significantly higher in the CF group as compared
to the wild-type group. These data indicate that tissue integrity
and regulation of immune responses are imbalanced in the
lungs of F508del-CF mice.
3.1. Acutely LPS-induced inflammatory responses
The combined protocol consisting of intratracheal instilla-
tion of two consecutive LPS doses (50 μg and 100 μg, 24 h
and 3 h before BAL, respectively), used with the aim of tracking
both humoral and cellular markers of inflammatory responses,
was well tolerated by F508del-CF and wild-type mice, and
no mortality was observed.
LDH activity was shown to be influenced by LPS with ele-
vated enzyme activity being monitored in the presence of LPS
challenge in both CF and non-CF animals (Fig. 1A). However,
the degree of response to LPS was apparently related to the ge-
notype. Indeed, the final level of LDH activity was significantly
higher in LPS challenged CF animals as compared to LPS chal-
lenged wild-type animals (Fig. 1A; p: 0.0003).
Total cell density and composition profile in BAL obtained
from F508del-CF and wild-type mice were significantly modifiedfollowing LPS (Fig. 1B,C). As an efficient neutrophil-infiltrating
model, LPS challenge promoted a dramatic increase in BAL
neutrophil counts which averaged 271.4 (37.3) x 103 in the
wild-type group and 375.9 (43.2) x 103 in the CF group. The ef-
fect of LPS challenge on neutrophil responses was apparently
influenced by the presence of F508del-CFTR mutation, as the
difference between CF and non-CF groups reached statistical
significance (Fig. 1 C; p=0.04). The combined LPS protocol
was also efficient to promote a macrophage-infiltrating response.
Indeed, under LPS influence, macrophage counts were increased
about 2-fold in wild-type mice and 3-fold in CF mice. The cell
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Fig. 2. Neutrophil-related and macrophage-related chemokine and pro-inflammatory cytokine concentration in the bronchoalveolar lavage (BAL) under baseline con-
ditions and after intratracheal instillation of LPS from Pseudomonas aeruginosa in wild-type (WT; white bars) and F508del-CF (black bars) mice, with and without
pre-treatment of vardenafil (0.14 mg/kg body weight), given in a single intraperitoneal administration. Macrophage inflammatory protein-2 (MIP-2; panel A);
chemokine (C-X-C motif) ligand 1 (CXCL-1 or KC; panel B); chemokine C-C motif ligand-2 (CCL-2; panel C); tumor necrosis factor-alpha (TNF-α; panel D;
interleukin 6 (IL-6; panel E) and interleukin 1beta (IL-1β; panel F). Values are means±SEM obtained from 4–8 animals per group from 2 representative experiments.
p values denote levels of significance measured in vardenafil-treated group compared with the corresponding non-treated group or to the wild-type group.
269B. Lubamba et al. / Journal of Cystic Fibrosis 11 (2012) 266–273composition profile under LPS challenge, as compared to control
conditions, was accordingly changed in both groups. The macro-
phage predominance was reversed to 13% in the wild-type group
and to 8.4% in the CF group.
As expected, responses to LPS of humoral inflammatory
markers were significantly increased in both non-CF and CF
groups (Fig. 2A-F). However, differences in the magnitude of
responses were revealed between the two groups. Except for
IL-1β (Fig. 2 F), response levels of chemokines (MIP-2, KC
and CCL-2; Fig. 2A-C) as well as of pro-inflammatory cyto-
kines (IL-6 and TNF-α; Fig. 2D-E) were much higher in
F508del-CF than in wild-type mice. These data indicate that
acutely induced humoral immunoresponses are overly exagger-
ated in the lungs of F508del-CF mice.
3.2. Vardenafil treatment
Treatment with vardenafil was well tolerated by non-CF and
CF animals and no adverse effect was observed. Under control
conditions, vardenafil seems to have a tissue protective effect in
CF lungs. Treatment with the drug reduced by 30% the sponta-
neously increased LDH activity in CF mice; the enzymeactivity was brought back to control reference values obtained
in wild-type mice. No detectable changes in LDH activity
were observed in the control wild-type group (Fig. 1A). The
drug seems also to have a genotype-unrelated tissue protective
effect against acute inflammatory responses (Fig. 1A). Under
LPS-induced inflammation, vardenafil reduced responses in
LDH activity by 55% in wild-type mice and by 35% in
F508del-CF mice.
Vardenafil did not significantly influence BAL cell counts
and composition profile in saline treated wild-type mice
(Fig. 1B,C). However, treatment with vardenafil to non LPS
challenged CF animals trended to attenuate neutrophil infiltra-
tion in BAL (Fig. 1 C; p=0.05). Moreover, treatment with
the drug significantly attenuated LPS-induced cell infiltrating
effect in both CF and non-CF animals. Indeed, under the influ-
ence of vardenafil, BAL total cell count was reduced by 2.3-
fold (p=0.002) in the wild-type group and by 3.5-fold
(p=0.002) in the F508del-CF group (Fig. 1B). Alveolar macro-
phage infiltrate in response to LPS induction was attenuated
by vardenafil treatment in the CF group only. Indeed, under
vardenafil influence, macrophage counts in LPS-challenged
CF animals changed from 34.5 (5.5) x 103 to 15.3 (3.9) x
270 B. Lubamba et al. / Journal of Cystic Fibrosis 11 (2012) 266–273103, which did not differ to those values found in CF control
conditions (13.4 (2.7) x 103; p=0.35 for the comparison be-
tween vardenafil-pretreated LPS challenged and saline-treated
CF mice). No effect of vardenafil was detected on macrophage
counts in the LPS-challenged wild-type group (p=0.47 forFig. 3. Hematoxylin and eosin-stained lung sections obtained from wild-type (A-C) o
ical abnormalities in wild-type (A) nor in the F508del-CF mice (D). B and E obtaine
fuse bronchopneumonia with more marked neutrophil infiltration in CF (E). C and F
by induction of inflammation with LPS from Pseudomonas aeruginosa: strong attenu
macrophages in alveoli (inserts). Bars correspond to 50 μm in large panels (A-F) ancomparison between vardenafil-pretreated LPS challenged and
saline-treated wild-type groups).
As for the expression of cyto/chemokines, no detectable
effect of vardenafil treatment could be observed under control
conditions in any genotype group. In contrast, under LPSr F508del-CF mice (D-F). A and D obtained from untreated mice: no patholog-
d after induction of inflammation with LPS from Pseudomonas aeruginosa: dif-
obtained after pre-treatment with vardenafil (0.14 mg/kg body weight) followed
ation of the cell infiltration. Arrows identify neutrophils and arrowheads identify
d to 10 μm in the inserts.
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sponse approximately by half in F508del-CF and in wild-type
mice (Fig. 2A). The downregulating effect of vardenafil on
LPS-induced expression of neutrophil chemoattraction was
confirmed on KC production which was reduced also by half
in both F508del-CF and wild-type mice (Fig. 2B). The immu-
nomodulatory effect of vardenafil was confirmed on responses
of pro-inflammatory TNF-α, IL-6 and IL-1β (Fig. 2D-F).
Indeed, both F508del-CF and wild-type mice treated with var-
denafil showed a lessened (1.5 to 3 times lower) production
of cytokines as compared to the corresponding non-vardenafil
pre-treated LPS challenged group. Under influence of vardena-
fil, significant reduction (by 66%) in CCL-2 response was
observed in the LPS-challenged CF group, but not in the corre-
sponding wild-type group. Additionally, IL-1β response was
significantly attenuated by vardenafil in CF only.
Histopathological examination (Fig. 3A-F) confirmed in
both genotypes the massive lung accumulation of neutrophils
in response to LPS, and its strong attenuation by vardenafil
treatment (Fig. 3A-F).
Altogether, these data indicate that vardenafil has an anti-
inflammatory effect that seems to be more pronounced in
F508del-CF mice, in particular on macrophage infiltration,
CCL-2 and IL-1β responses. Additionally, the drug appears
to have a tissue protective effect in CF lungs.4. Discussion
The present study was designed to test the hypothesis that
vardenafil, a PDE5 inhibitor, applied in vivo at a single clinical
dose, modulates lung inflammation in CF. We have previously
demonstrated that intraperitoneal [8] or aerogenous [9] adminis-
tration of a clinical dose of vardenafil partially corrects CFTR-
dependent chloride transport defects across the nasal mucosa
of F508del-CF mice. As lung inflammation plays a major role
in morbi-mortality in CF, identifying a molecule that combines
correction of the basic ion transport defect and modulation of
dysregulated inflammatory responses in CF is very exciting and
promising. Because vardenafil is in clinical use, our work may
have a short-term impact to the clinical setting.
We confirmed here that F508del-CF mice exhibit a spontane-
ous lung inflammation [6] characterized by increased LDH activ-
ity, accumulation of neutrophils and up-regulation of MIP-2
neutrophil-attractant chemokine and TNF-α pro-inflammatory
cytokine. Neutrophilic infiltration was likely related to increased
levels of MIP-2, a key chemokine functionally equivalent to
the human IL-8 that has long been recognized as a critical cyto-
kine in CF lung inflammation [13]. IL-8 up-regulation by early
TNF-α responses involves several major intracellular pathways,
including NF-κB. TNF-α is also involved in lung neutrophilic
infiltration and is chiefly produced by activated macrophages
[14,15]. In agreement with previous works [4–6], we confirmed
here that pro-inflammatory responses to LPS from P. aeruginosa
are overly exaggerated in lungs of F508del-CF mice, suggesting
that in CF a latent inflammatory imbalance may increase the
sensitivity to acute inflammatory challenge.Our data suggest that vardenafil have, even under control con-
ditions, a tissue protective role in lungs expressing the mutated
F508del-CFTR. A genotype-unrelated tissue protective effect of
vardenafil was also apparent after induction of inflammation.
The genotype-unrelated anti-inflammatory effect of vardenafil,
characterized by attenuation of LPS-induced neutrophil cell infil-
tration, neutrophil-chemoattractant markers (MIP-2 and KC) and
pro-inflammatory cytokines (IL-6 and TNF-α), could possibly be
attributed to the consequent increase in intracellular cGMP levels
in lungs. PDE5, originally named cGMP-PDE based on its high
affinity for cGMP, has been characterized in lungs [16,17].
In mice models of LPS-induced inflammation, inhibition of solu-
ble guanylyl cyclase, that catalyzes the generation of cGMP,
worsens lung inflammation, and this can be reversed by a cell-
permeant cGMP analogue [18]. Zaprinast, a potent PDE5 inhibi-
tor known as a relaxant of airway smooth muscle, can reduce
LPS-mediated IL-6 and TNF-α production in primary cultures
of rat alveolar epithelial cells [19]. In mice exposed to bacterial
aerosol, sildenafil reduced LPS mediated lung neutrophil infiltra-
tion [20] and attenuated acrolein-induced airway inflammation
and mucus production, possibly through restoring the cGMP
pathway [21].
Together with the distinct attenuating effect on CF IL-1β re-
sponses, the finding that immunomodulation of responses of
macrophages and of CCL2, an essential chemoattractant for
macrophages and blood monocytes also called MCP-1 (mono-
cyte chemoattractant protein-1), were only seen in F508del-
CF mice would suggest that macrophages may represent, at
least partly, a target-effector cell of the anti-inflammatory effect
of vardenafil in CF. Recent data indicated that macrophage ex-
presses functional CFTR [22] and that the cell density and its
apparent link to CCL-2 levels are ubiquitously increased in
CF [23]. Moreover, macrophage cell differentiation is dysregu-
lated in CF disease [23]. We have also previously shown [23]
that expression of IL-1β, a proinflammatory cytokine closely
linked to the innate immunity [24], is upregulated in CF alveolar
and peritoneal macrophages even in naive, non stimulated condi-
tions. It has been recognized that innate immunity is critical for
clearing P. aeruginosa from the lungs and that IL-1β release and
intracellular signaling pathways in response to bacterial infection
are deficient in cells lacking functional CFTR [25]. It has also
been suggested that polymorphic variants in IL-1β gene could
account for heterogeneity in pulmonary disease severity [26].
In CF respiratory epithelial cultured cells, increasing cGMP
levels would correct multiple aspects of the CF pathological
cascade, including defective protein glycosylation, bacterial ad-
herence and pro-inflammatory responses [20,27–29]. Recent
data have shown that cyclic nucleotides and phosphodiesterases
regulate monocyte/macrophage differentiation processes with
regard to surface marker expression, gene expression or changes
in secreted chemokine and cytokine levels [30]. Induction of
proinflammatory activation of Kupffer cells, a differentiated he-
patic monocyte cell subpopulation, in wild-type mice is coinci-
dent with reduced liver endothelial NO synthase activity and
NO content while, conversely, enhancement of signaling down-
stream of NO-cGMP pathway through PDE5 inhibition has a pro-
tective and anti-inflammatory effect in Kupffer cells [31]. Further
272 B. Lubamba et al. / Journal of Cystic Fibrosis 11 (2012) 266–273studies are needed to better understand the mechanism of anti-
inflammatory action of vardenafil in CF, particularly in CF mac-
rophage cells. Studies using CF mice or human epithelial cell
lines displaying different genotypes could be helpful to address
the question whether the effects of vardenafil we observed here
are specific or not for the F508del mutation. Even though a
clear link between the immunomodulatory activity reported
here and the correction of ion transport abnormalities previously
reported [8,9] could not be firmly established in the present work,
it is interesting to note that similar anti-inflammatory properties
have been demonstrated for another F508del-CF activating
drug, miglustat [10]. As a matter of fact, wild-type mice treated
with miglustat, an orally available iminosugar used in the treat-
ment of Gaucher disease that is also able to correct ion transport
across the nasal mucosa of F508del-CF mice [32], showed a re-
duced number of neutrophils and KC in the airways in response
to challenge with LPS [10]. The fact that reduced inflammatory
markers were observed even in the presence of wild-type CFTR
protein might support the view that vardenafil acts as a CFTR
potentiator. Interestingly, in our previous functional studies [8],
vardenafil, but not sildenafil, was able to increase chloride trans-
port activity through wild-type CFTR. As aerogenous adminis-
tration of vardenafil was shown to be effective on chloride
conductance [9], further preclinical studies should be designed
to compare the effects described here with those obtained after
drug inhalation. Eventual confirmation of anti-inflammatory
effects of vardenafil under inhalational exposure in F508del-
CF mice would provide more relevant therapeutic perspectives
for CF patients.
In summary, our data support the concept that inflammation
may occur even in the absence of any detectable infection and
highlight F508del-CF mice as an interesting model to decipher
the inflammation phenotype and inflammatory responses of
CF lung disease. Our data also confirm that inflammatory re-
sponses are overly exaggerated in CF. We have shown here
the benefits of vardenafil treatment, administered in vivo at a
clinical dose on the blockade of airway inflammation mediated
by P. aeruginosa endotoxin. The results suggest that vardenafil
might have therapeutic potential for counteracting inflammato-
ry signals in CF lung disease. As chronic lung inflammation
in CF results in critical compromise of the prognosis of the dis-
ease, our findings are of great clinical relevance.
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